Relevant bibliographies by topics / Tumour / Journal articles
To see the other types of publications on this topic, follow the link: Tumour.

Journal articles on the topic 'Tumour'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Tumour.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Khatri, R. "Clinicopathological Analysis of Ovarian Tumours at Birendra Military Hospital." Medical Journal of Shree Birendra Hospital 10, no. 1 (July 16, 2012): 26–31. http://dx.doi.org/10.3126/mjsbh.v10i1.6446.

Full text
Abstract:
Introduction: Ovarian cancer is the second most common genital tract malignancy accounting for 25% gynaecological malignancy. This study was conducted to determine the incidence, epidemiological factors and clinical presentation of different types of ovarian tumours their correlation with histopathology. Methods: This is a descriptive study conducted in Birendra Military Hospital over a period of 2 years. The case records of all the patients with ovarian tumur was analyzed. Results: Of the total of 135 adnexal masses cases 100 (74.07%) were found to be histologically proven ovarian tumour out of which 35 were non neoplastic conditions. Benign tumours comprised of 68 (68%) and 32 (32%) were malignant and borderline.Mature cystic teratoma 28 (75%) was the commonest benign tumour, whereas serous cystadenocarcinoma 13 (64.3%) were commonest malignancy. Age varying from 2.5 yrs. To 70 yrs. Smallest tumour size was 2.5 cm. largest was 40 cm. Commonest symptom was abdominal discomfort and most common sign was abdominal lump. Malignancy usually presented with ascites especially epithelial ovarian tumours. Germ cell tumour was observed in younger age group in earlier stage. Conclusion: The commonest ovarian tumor was epithelial followed by germcell. Mature cystic teratoma was the most common benign tumour and malignant was serous cyst adenocarcinoma. Epithelial ovarian tumour prevalent in perimenopausal and postmenopausal age group whereas germ cell in earlier age. DOI: http://dx.doi.org/10.3126/mjsbh.v10i1.6446 Medical Journal of Shree Birendra Hospital Jan-June 2011 10(1) 26-31
APA, Harvard, Vancouver, ISO, and other styles
2

Ahmed, Mousumi, Nazma Afroze, and Mahjabin Sabiha. "Morphological Pattern of Ovarian Tumour : Experience in a Tertiary Level Hospital." Journal of Bangladesh College of Physicians and Surgeons 36, no. 1 (January 29, 2018): 5–10. http://dx.doi.org/10.3329/jbcps.v36i1.35504.

Full text
Abstract:
Background: Ovarian tumor is a common type of gynecological neoplasm and accounts for 15-25% of all gynecological malignancies. It is associated with high mortality and an accurate histological diagnosis is essential for management of patient.Objective: The study was performed to find out the morphological pattern, nature and age distribution of ovarian tumour in our hospital.Material and methods: It was a prospective study,conducted in the Department of Histopathology and Cytopathology, BIRDEM General Hospital, Dhaka for a period of two years from Jan 2014 to Dec 2015. This study included 186 cases of ovarian tumors sent in the Department of Pathology for histopathological evaluation. Non-neoplastic lesions and tumour-like conditions were excluded from the study. Histological diagnosis, age and laterality of ovary were recorded. Morphological pattern, nature and age distribution of ovarian neoplasms were calculated.Result: 84.95% cases of ovarian tumour were benign, 1.61% cases were borderline and 13.44% cases were malignant. ORIGINAL ARTICLES Surface epithelial tumour was the commonest type of tumour (61.83%), according to the histogenesis , followed by germ cell tumour. Benign serous tumour was the most common type of benign tumor (37.98% cases), followed by mature cystic teratoma (33.55% cases). Serous cystadenocarcinoma was the most common type of malignant tumour (36.0%), followed by endometrioid carcinoma (28.0%). Benign tumours were more frequent in all age group. The incidence of malignant ovarian tumour increased with age and was most frequent in >50 years age group. Benign tumours were commonly cystic, whereas malignant tumours were commonly solid and cystic. 11.23% cases of ovarian tumours were bilateral.Conclusion: Benign ovarian neoplasms were more common than malignant ones and benign serous tumour was the commonest type of benign neoplasm whereas serous cystdenocarcinoma was the commonest type of malignant neoplasm. The pattern and age distribution of ovarian tumour of our study were quite similar with other studies with some variation.J Bangladesh Coll Phys Surg 2018; 36(1): 5-10
APA, Harvard, Vancouver, ISO, and other styles
3

Kandemirli, S. G., A. Reddy, P. Hitchon, J. Saini, and G. Bathla. "Intramedullary tumours and tumour mimics." Clinical Radiology 75, no. 11 (November 2020): 876.e17–876.e32. http://dx.doi.org/10.1016/j.crad.2020.05.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Magetsari, Rahadyan, Hengkie Marseno, Zikrina Lanodiyu, and Punto Dewo. "Accuration of Fine Needle Aspiration Biopsy in Musculoskeletal Tumour." International Journal of Public Health Science (IJPHS) 5, no. 2 (June 1, 2016): 134. http://dx.doi.org/10.11591/ijphs.v5i2.4776.

Full text
Abstract:
Fine needle aspiration biopsy (FNAB) has been reported to be the preferable choice of biopsy for musculoskeletal tumour. While FNAB appears to have advantages to core biopsy in the aspect of simplicity and cost, the diagnostic accuracy should be the most critical parameter in determining the choice of biopsy. This research was designed to evaluate the diagnostic accuracy of fine needle aspiration in musculoskeletal tumour in Sardjito Hospital from 2010 until 2014. This was a descriptive study from medical record in Sardjito Hospital from 2010 until 2014. The inclusion criteria are musculoskeletal tumours in all age level that has been performed FNAB with subsequent operative treatment and confirmation of histopathology examination in Sardjito Hospital. There were 41 elligible subjects in this study. Concordance diagnosis of FNAB and histopathological examination in all musculoskeletal tumor cases was found to be 86%. In addition, the concordance in soft tissue tumor cases was 94% with the detail as follows: giant cell tumor was 86%, synovial sarcoma was 50% and liposarcoma was 50%. In bone tumours, the accuracy was found to be 60% with the detail as follows: distribute osteosarcoma was 60%, osteochondroma was 50% and chondrosarcoma was 50%. Our data showed that accuracy of FNAB for diagnosis of musculoskeletal tumours was 86% with soft tissue tumour 94%, bone tumour 60% and others 93%. Therefore, Fine needle aspiration biopsy is still important diagnosis tool in musculoskeletal tumours.
APA, Harvard, Vancouver, ISO, and other styles
5

Magetsari, Rahadyan, Hengkie Marseno, Zikrina Lanodiyu, and Punto Dewo. "Accuration of Fine Needle Aspiration Biopsy in Musculoskeletal Tumour." International Journal of Public Health Science (IJPHS) 5, no. 2 (June 1, 2016): 134. http://dx.doi.org/10.11591/.v5i2.4776.

Full text
Abstract:
Fine needle aspiration biopsy (FNAB) has been reported to be the preferable choice of biopsy for musculoskeletal tumour. While FNAB appears to have advantages to core biopsy in the aspect of simplicity and cost, the diagnostic accuracy should be the most critical parameter in determining the choice of biopsy. This research was designed to evaluate the diagnostic accuracy of fine needle aspiration in musculoskeletal tumour in Sardjito Hospital from 2010 until 2014. This was a descriptive study from medical record in Sardjito Hospital from 2010 until 2014. The inclusion criteria are musculoskeletal tumours in all age level that has been performed FNAB with subsequent operative treatment and confirmation of histopathology examination in Sardjito Hospital. There were 41 elligible subjects in this study. Concordance diagnosis of FNAB and histopathological examination in all musculoskeletal tumor cases was found to be 86%. In addition, the concordance in soft tissue tumor cases was 94% with the detail as follows: giant cell tumor was 86%, synovial sarcoma was 50% and liposarcoma was 50%. In bone tumours, the accuracy was found to be 60% with the detail as follows: distribute osteosarcoma was 60%, osteochondroma was 50% and chondrosarcoma was 50%. Our data showed that accuracy of FNAB for diagnosis of musculoskeletal tumours was 86% with soft tissue tumour 94%, bone tumour 60% and others 93%. Therefore, Fine needle aspiration biopsy is still important diagnosis tool in musculoskeletal tumours.
APA, Harvard, Vancouver, ISO, and other styles
6

Hwee Tang, Phua, and Sameema Nisa. "OTHR-10. Pilocytic astrocytoma with respect to treatment." Neuro-Oncology 24, Supplement_1 (June 1, 2022): i149. http://dx.doi.org/10.1093/neuonc/noac079.549.

Full text
Abstract:
Abstract AIM: To describe the sizes of pilocytic astrocytoma with respect to treatment Methodology Pediatric pilocytic astrocytomas cases from 2001 to 2021 were retrospectively reviewed in this Institutional Review Board approved study. Imaging reports, location of tumour, maximum dimension of tumour at diagnosis, treatment given (operation/chemotherapy/ radiotherapy), degree of tumor excision were captured. RESULTS: Imaging was available in 33 with 23 centered in the posterior fossa (1 extending into thalamus), 4 in suprasellar region, 2 in cerebral hemisphere, 2 in thalamus, 1 in pineal thalamic region and 1 in cervicomedullary spine, Tumor dimension at presentation was 5.40 cm ± 2.34 cm. Tumor size at presentation did not show significant correlation with age. 30 patients underwent operation with tumours completely excised in 15 and partially excised in 14 and no postoperative information for 1. Three patients, where tumour involved the thalamus, did not have operation and were given radiotherapy, average size of tumour being 3.47 + 1.15 cm. compared to the 5.59 + 2.34 size of tumours that underwent operation (p=0.06). Completely excised tumours measured 6.29 ± 2.04 cm at presentation while incompletely excised ones measured 4.76 ± 2.53 cm, not significantly different (p=0.09). Unoperated tumours are statistically smaller than those completely excised (p=0.02). One of the completetly excised tumours was located in the parietal cerebral hemisphere with the rest of the 15 in the posterior fossa. Seven of the incompletely excised tumours were located in the posterior fossa with 4 in suprasellar region, 1 in thalamus, 1 in spine and 1 in cerebral hemisphere. 3 patients with uncompletely excised tumours (1 cerebral, 1 post fossa, 1 spine) had post-operative radiation while 2 suprasellar tumours were given post-operative chemotherapy. CONCLUSION: Completely excised tumours are mainly located in posterior fossa. Tumours not operated on are located in thalamus and significantly smaller than tumours which are completely excised.
APA, Harvard, Vancouver, ISO, and other styles
7

Qureshi, Asim, Mansour Al-Moundhri, Maha Al-Shaibi, Ibrahim Al-Haddabi, and Alok Mittal. "Primary Gastric Yolk Sac Tumour." Sultan Qaboos University Medical Journal [SQUMJ] 18, no. 3 (December 19, 2018): 383. http://dx.doi.org/10.18295/squmj.2018.18.03.020.

Full text
Abstract:
Primary gastric yolk tumours are extremely rare. We report a 52-year-old male who presented to the Sultan Qaboos University Hospital, Muscat, Oman, in 2017 after having undergone a gastrectomy abroad due to a suspected poorly-differentiated adenocarcinoma. The patient subsequently returned to Oman to receive chemotherapy. However, while undergoing chemotherapy, an abdominal computed tomography scan revealed a lobulated mesenteric mass. Microscopic examination of the resected lesion confirmed a diagnosis of a yolk sac tumour. The mass was diffusely positive for α-fetoprotein (AFP) and a gastric carcinoma stain was negative. Gastrectomy slides from the patient’s previous surgery were examined retrospectively. The morphology was typical for a yolk sac tumour and was negative for epithelial markers. An AFP stain showed diffuse immunoreactivity. Thus, the patient was deemed to have had a primary gastric yolk sac tumour which had later metastasised to the mesocolon. Germ cell tumour protocols were initiated and the patient responded well to treatment.Keywords: Yolk Sac Tumor; Germ Cell Tumor; Gastrectomy; Metastasis; Diagnostic Errors; Case Report; Oman.
APA, Harvard, Vancouver, ISO, and other styles
8

Szymanski, Konrad M., Abdulaziz Baazeem, Kanishka Sircar, Simon Tanguay, and Wassim Kassouf. "Primary renal carcinoid tumour with inferior vena caval tumour thrombus." Canadian Urological Association Journal 3, no. 3 (April 26, 2013): 7. http://dx.doi.org/10.5489/cuaj.1091.

Full text
Abstract:
Carcinoid tumours, most frequently reported in the gastrointestinaland respiratory tracts, are exceedingly rare primary renal cancers.Few cases have been published to date. To our knowledge,we report the first case of a primary carcinoid tumour of the kidneysinvolving the inferior vena cava. We treated a 58-year-oldwoman with an open radical nephrectomy and cavotomy withthrombectomy. We describe the presentation, investigations andpathology results. We discuss the current experience with carcinoidtumours as a literature review relating to the diagnosis of thedisease and the prognosis of patients with this neoplasm. Localizedcarcinoid tumours of the kidneys, including those involving thevena cava, can be successfully treated with surgical excision.Les carcinoïdes, principalement observés dans le tractus digestifet les voies respiratoires, sont des tumeurs rénales primitivesextrêmement rares. Quelques cas seulement ont été publiés jusqu’àprésent. Nous décrivons le premier cas de carcinoïde primitifdu rein touchant la veine cave inférieure. Nous avons traité lapatiente, âgée de 58 ans, par néphrectomie radicale ouverte etthrombectomie par cavotomie. Nous présentons ici les détailsdu cas au moment de la consultation, les examens effectués et lesrésultats des analyses de pathologie. Le niveau actuel d’expérienceavec ce type de tumeur est discuté sous forme de revue dela littérature en lien avec le diagnostic et le pronostic. Les carcinoïdeslocalisés du rein, y compris ceux touchant la veine cave,peuvent être traités avec succès par excision chirurgicale.
APA, Harvard, Vancouver, ISO, and other styles
9

Elouarith, Ihssan, Leila Benbella, Fouad Zouaidia, Ahmed Jahid, Zakia Bernoussi, and Kaoutar Znati. "Intracranial Solitary Fibrous Tumour: Case Report." Scholars Journal of Medical Case Reports 11, no. 08 (August 2, 2023): 1454–57. http://dx.doi.org/10.36347/sjmcr.2023.v11i08.008.

Full text
Abstract:
Intracranial solitary fibrous tumor is a rare mesenchymal tumour. The diagnosis is based on the histological study given the clinical and radiological character that can simulate other benign or malignant pathologies especially meningioma. We report the case of a patient with an intracranial solitary fibrous tumor. We aim to discuss the clinical, radiological, histological and immunohistochemical features of Intracranial solitary fibrous tumor as well as the new grading system reported in the fifth edition of the WHO classification of central nervous system tumours.
APA, Harvard, Vancouver, ISO, and other styles
10

Bindal, Jyoti, and Sangeeta Bankey. "Prevalence of ovarian tumours among ovarian mass lesions in Gajra Raja Medical College, Gwalior, India." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 6, no. 9 (August 28, 2017): 3907. http://dx.doi.org/10.18203/2320-1770.ijrcog20174032.

Full text
Abstract:
Background: Ovarian tumor is one of the most common gynecological tumors seen in female although there are different types of ovarian tumor but epithelial ovarian cancer is the fifth most common cause of cancer death in women. It is often called the “silent killer” because the disease is not often detected until it reaches an advance stage.Methods: This observational study conducted on 130 patients from February 2015 to March 2017 in the Department of Obstetrics and Gynaecology in Gajra Raja Medical College, Gwalior. Clinical details of the patients included age, gynaecological and obstetric history, presenting symptoms, and surgery details. Histopathological reporting was done at our Pathology department.Results: Out of total 130 patients with ovarian tumours studied 49.2% were > 60 years of age group, most of them were nullipara (53.8%), 54.6% with ovarian tumours presented after one-year development of symptoms. most of the symptoms were vague and nonspecific. Benign tumours were the most prevalent (79.2%), 19.2% were malignant tumours and 1.5% were borderline. Histological pattern of distribution of ovarian tumour shows that most of ovarian tumour were surface epithelial tumour (72 patients) followed by germ cell tumour (58 patients). Age wise distribution of study population showed that most of the surface epithelial tumour were more common in 3rd to 5th decade while most of germ cell tumour were more frequent in 2nd and 3rd decade.Conclusions: For better prognosis and patient survival, early detection and treatment is mandatory, which may reduce mortality. There is need to increase awareness of population. Abdominal and pelvic bimanual examination should be carried out in every patient presenting with gynecological problem. Appropriate investigations in post-menopausal women in early period to diagnose the disease at an early stage.
APA, Harvard, Vancouver, ISO, and other styles
11

Zheng, Lin-Lin, Ya-Ru Wang, Zhen-Rong Liu, Zhi-Hao Wang, Chang-Cheng Tao, Yong-Gang Xiao, Kai Zhang, et al. "High spindle and kinetochore-associated complex subunit-3 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1600–1614. http://dx.doi.org/10.4240/wjgs.v15.i8.1600.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
12

Fiflis, Stylianos, Menelaos Papakonstantinou, Alexandros Giakoustidis, Gregory Christodoulidis, Eleni Louri, Vasileios N. Papadopoulos, and Dimitrios Giakoustidis. "Comparison between upfront surgery and neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A systematic review." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1808–18. http://dx.doi.org/10.4240/wjgs.v15.i8.1808.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
13

Ito, Renma, Kazuhiro Miwa, and Yutaka Matano. "Outpatient hybrid endoscopic submucosal dissection with SOUTEN for early gastric cancer, followed by endoscopic suturing of the mucosal defect: A case report." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1831–37. http://dx.doi.org/10.4240/wjgs.v15.i8.1831.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
14

Wang, Rui, Ya Liu, Yan Liang, Li Zhou, Mao-Jia Chen, Xu-Bao Liu, Chun-Lu Tan, and Yong-Hua Chen. "Regional differences in islet amyloid deposition in the residual pancreas with new-onset diabetes secondary to pancreatic ductal adenocarcinoma." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1703–11. http://dx.doi.org/10.4240/wjgs.v15.i8.1703.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
15

Pang, Li-Qun, Jie Zhang, Fang Shi, Cong Pang, Cheng-Wan Zhang, Ye-Liu Liu, Yao Zhao, et al. "Anti-reflux effects of a novel esophagogastric asymmetric anastomosis technique after laparoscopic proximal gastrectomy." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1761–73. http://dx.doi.org/10.4240/wjgs.v15.i8.1761.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
16

Peparini, Nadia. "Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1559–63. http://dx.doi.org/10.4240/wjgs.v15.i8.1559.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
17

Aploks, Krist, Minha Kim, Stephanie Stroever, Alexander Ostapenko, Young Bo Sim, Ashwinkumar Sooriyakumar, Arash Rahimi-Ardabily, Ramanathan Seshadri, and Xiang Da Dong. "Radiation therapy prior to a pancreaticoduodenectomy for adenocarcinoma is associated with longer operative times and higher blood loss." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1663–72. http://dx.doi.org/10.4240/wjgs.v15.i8.1663.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
18

Wang, Lan-Jing, Xin Yao, Qi Qi, and Jian-Ping Qin. "Prevention and treatment of hepatic encephalopathy during the perioperative period of transjugular intrahepatic portosystemic shunt." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1564–73. http://dx.doi.org/10.4240/wjgs.v15.i8.1564.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
19

Yang, Qun-Ying, Qian Zhao, and Jian-Wen Hu. "Is endoscopic mucosal resection-precutting superior to conventional methods for removing sessile colorectal polyps?" World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1838–40. http://dx.doi.org/10.4240/wjgs.v15.i8.1838.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
20

Yang, Xiao-Yun, Cong Wang, Yi-Ping Hong, Ting-Ting Zhu, Lu-Jia Qian, Yi-Bing Hu, Li-Hong Teng, and Jin Ding. "Knowledge, attitude, and practice of monitoring early gastric cancer after endoscopic submucosal dissection." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1751–60. http://dx.doi.org/10.4240/wjgs.v15.i8.1751.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
21

Qi, Wei-Li, Jun Wen, Tian-Fu Wen, Wei Peng, Xiao-Yun Zhang, Jun-Yi Shen, Xiao Li, and Chuan Li. "Prognosis after splenectomy plus pericardial devascularization vs transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1641–51. http://dx.doi.org/10.4240/wjgs.v15.i8.1641.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
22

Gong, Yong-Qiang, Tai-Liang Lu, and Chao-Wu Chen. "Long-term survival of patients with hepatocellular carcinoma with hepatic, pulmonary, peritoneal and rare colon metastasis: A case report." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1819–24. http://dx.doi.org/10.4240/wjgs.v15.i8.1819.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
23

Feng, Juan, Jia-Min Xu, Hai-Yan Fu, Nan Xie, Wei-Min Bao, and Ying-Mei Tang. "Prognostic scores in primary biliary cholangitis patients with advanced disease." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1774–83. http://dx.doi.org/10.4240/wjgs.v15.i8.1774.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
24

Chen, Ke, Ming Li, Ran Xu, Ping-Ping Zheng, Meng-Ding Chen, Liang Zhu, Wen-Bin Wang, and Zheng-Guang Wang. "Changing trends in gastric and colorectal cancer among surgical patients over 85 years old: A multicenter retrospective study, 2001–2021." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1739–50. http://dx.doi.org/10.4240/wjgs.v15.i8.1739.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
25

Xu, Xiao-Yan, Hui-Ping Xue, Ming-Jun Yuan, You-Rong Jin, and Chun-Xia Huang. "Effects of ultrasound monitoring of gastric residual volume on feeding complications, caloric intake and prognosis of patients with severe mechanical ventilation." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1719–27. http://dx.doi.org/10.4240/wjgs.v15.i8.1719.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
26

Cui, Da-Peng, Shuang Fan, Ying-Xue Guo, Qian-Wei Zhao, Yue-Xin Qiao, and Jian-Dong Fei. "Accurate resection of hilar cholangiocarcinoma using eOrganmap 3D reconstruction and full quantization technique." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1693–702. http://dx.doi.org/10.4240/wjgs.v15.i8.1693.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
27

Li, Dong-Xia, Wei Ye, Yi-Lu Yang, Lei Zhang, Xiang-Jun Qian, and Ping-Hua Jiang. "Enhanced recovery nursing and mental health education on postoperative recovery and mental health of laparoscopic liver resection." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1728–38. http://dx.doi.org/10.4240/wjgs.v15.i8.1728.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
28

Qi, Rui-Zhao, Zhi-Wei Li, Zheng-Yao Chang, Wei-Hua Chang, Wen-Lei Zhao, Chuan Pang, Ying Zhang, Xing-Long Hu, and Feng Liang. "Clinical efficacy of total laparoscopic splenectomy for portal hypertension and its influence on hepatic hemodynamics and liver function." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1684–92. http://dx.doi.org/10.4240/wjgs.v15.i8.1684.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
29

Walia, Dinesh, Anoop Saraya, and Deepak Gunjan. "Vascular complications of chronic pancreatitis and its management." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1574–90. http://dx.doi.org/10.4240/wjgs.v15.i8.1574.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
30

Jimenez-Romero, Carlos, Iago Justo-Alonso, Pilar del Pozo-Elso, Alberto Marcacuzco-Quinto, Cristina Martín-Arriscado-Arroba, Alejandro Manrique-Municio, Jorge Calvo-Pulido, Alvaro García-Sesma, Ricardo san Román, and Oscar Caso-Maestro. "Post-transplant biliary complications using liver grafts from deceased donors older than 70 years: Retrospective case-control study." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1615–28. http://dx.doi.org/10.4240/wjgs.v15.i8.1615.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
31

Liu, He-Li, Xiang Feng, Mi-Mi Tang, Hai-Yan Zhou, Huan Peng, Jie Ge, and Ting Liu. "Prognostic significance of preoperative lymphocyte to monocyte ratio in patients with signet ring gastric cancer." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1673–83. http://dx.doi.org/10.4240/wjgs.v15.i8.1673.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
32

Zhang, He-Zhao, Jun-Hui Lu, Zhi-Yong Shi, Ya-Rong Guo, Wen-Hao Shao, Fan-Xiu Meng, Rui Zhang, An-Hong Zhang, and Jun Xu. "Donor hepatic artery reconstruction based on human embryology: A case report." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1825–30. http://dx.doi.org/10.4240/wjgs.v15.i8.1825.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
33

Robertson, Francis P., Harry V. M. Spiers, Wei Boon Lim, Benjamin Loveday, Keith Roberts, and Sanjay Pandanaboyana. "Intraoperative pancreas stump perfusion assessment during pancreaticoduodenectomy: A systematic scoping review." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1799–807. http://dx.doi.org/10.4240/wjgs.v15.i8.1799.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
34

Augustin, Goran, Ivan Romic, Iva Miličić, Mislav Mikuš, and Mislav Herman. "Maternal choledochal cysts in pregnancy: A systematic review of case reports and case series." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1784–98. http://dx.doi.org/10.4240/wjgs.v15.i8.1784.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
35

Chang, Wei-Jung, Lien-Cheng Tsao, Hsu-Heng Yen, Chia-Wei Yang, Hung-Chi Chang, Chew-Teng Kor, Szu-Chia Wu, and Kuo-Hua Lin. "Goldilocks principle of minimally invasive surgery for gastric subepithelial tumors." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1629–40. http://dx.doi.org/10.4240/wjgs.v15.i8.1629.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
36

Li, Kai-Wei, Kai Wang, Yue-Peng Hu, Chao Yang, Yun-Xuan Deng, Xin-Yu Wang, Yu-Xiu Liu, Wei-Qin Li, and Wei-Wei Ding. "Initial suction drainage decreases severe postoperative complications after pancreatic trauma: A cohort study." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1652–62. http://dx.doi.org/10.4240/wjgs.v15.i8.1652.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
37

A, Ji-De, Jin-Ping Chai, Sheng-Long Jia, and Xiang-Ren A. "Historical changes in surgical strategy and complication management for hepatic cystic echinococcosis." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1591–99. http://dx.doi.org/10.4240/wjgs.v15.i8.1591.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
38

Chen, Jian-Hui, Mei-Fen Zhang, Wen-Chao Du, and Yan-An Zhang. "Risk factors and their interactive effects on severe acute pancreatitis complicated with acute gastrointestinal injury." World Journal of Gastrointestinal Surgery 15, no. 8 (August 27, 2023): 1712–18. http://dx.doi.org/10.4240/wjgs.v15.i8.1712.

Full text
Abstract:
Tumour rupture of gastrointestinal stromal tumours (GISTs) has been considered to be a remarkable risk factor because of its unfavourable impact on the oncological outcome. Although tumour rupture has not yet been included in the current tumor-node-metastasis classification of GISTs as a prognostic factor, it may change the natural history of a low-risk GIST to a high-risk GIST. Originally, tumour rupture was defined as the spillage or fracture of a tumour into a body cavity, but recently, new definitions have been proposed. These definitions distinguished from the prognostic point of view between the major defects of tumour integrity, which are considered tumour rupture, and the minor defects of tumour integrity, which are not considered tumour rupture. Moreover, it has been demonstrated that the risk of disease recurrence in R1 patients is largely modulated by the presence of tumour rupture. Therefore, after excluding tumour rupture, R1 may not be an unfavourable prognostic factor for GISTs. Additionally, after the standard adjuvant treatment of imatinib for GIST with rupture, a high recurrence rate persists. This review highlights the prognostic value of tumour rupture in GISTs and emphasizes the need to carefully take into account and minimize the risk of tumour rupture when choosing surgical strategies for GISTs.
APA, Harvard, Vancouver, ISO, and other styles
39

Raji T Naidu, Susan Cherian, Vaishnavi Kumba, and Uma Chaturvedi. "Sinonasal Glomangiopericytoma: A Case Report." International Journal of Head and Neck Pathology 5, no. 2 (August 22, 2022): 13–19. http://dx.doi.org/10.56501/intjheadneckpathol.v5i2.607.

Full text
Abstract:
Sinonasal glomangiopericytoma is defined as a low-grade malignant tumor demonstrating a perivascular myoid phenotype. We report a case of sinonasal glomangiopericytoma having a diffuse architecture with bland spindle cells arranged in short fascicles, storiform, whorled, reticular pattern, separated by a vascular plexus ranging from capillaries to large patulous spaces. Immunohistochemistry is required to differentiate it from other perivascular tumours and solitary fibrous tumour. However, differentiating glomangiopericytomas and solitary fibrous tumours based on immunohistochemistry is a challenge. The tumour expressed vimentin, focal smooth muscle actin and CD34, diffuse, strong Bcl2 and Beta catenin and negative STAT6. Immunohistochemical expression of STAT6 is useful as a negative marker in the diagnosis and separation of glomangiopericytoma from solitary fibrous tumour. Key Messages: Sinonasal glomangiopericytoma (SNGP), a rare tumour with low malignant potential as per WHO classification is frequently confused with sinonasal solitary fibrous tumour (SFT). This article emphasizes the importance of using a broader immunohistochemical panel of positive and negative markers for differentiating SNGP from SFT. The most useful among them being CD34, SMA, BCL2, Beta Catenin and STAT6.
APA, Harvard, Vancouver, ISO, and other styles
40

Pavlov, R. V., V. A. Aksionenko, and S. A. Selkov. "Cytokines production by mononuclear cells, infiltrating the epithelium tumour of ovaries." Journal of obstetrics and women's diseases 51, no. 1 (January 15, 2002): 74–77. http://dx.doi.org/10.17816/jowd90024.

Full text
Abstract:
At auto serum presence one investigated IL1, IL2, IL4, IL6 and TNF6 production by mononuclear cells, infiltrating epithelium tumor of ovaries in 50 women of the patients by good-quality tumors, 30 patients by boundary tumors and 50 patients by an ovarian carcinoma. It was established, that IL1, TNF6 and IL6 production by mononuclear cells, infiltrating epithelium tumour of ovary, grew at malignancy of good-quality tumors and decreased the differentiation degree of cells of ovarian carcinoma. At malignancy of good-quality tumours and decreasing differentiation degree of cells of ovarian carcinoma the decrease of spontaneous and stimulated production of IL2 and stimulated production of IL4 by mononuclear cells, infiltrating epithelian tumour of ovary is revealed. The received data allow approving the increase of activity of mononuclear fagocytes, infiltrating epithelian tumor of ovarian during tumour progression, and also the decrease of T-cells activity in the 1-st and 2 types of immunity reactions in tumours of this localization. One of the possible reasons of cells immunity decrease at a tissue level in ovarian tumour can be increased production of cytokines by mononuclears, closing immunity reactions, in particular IL6.
APA, Harvard, Vancouver, ISO, and other styles
41

Bhat, Javaid Ahmad, Syed Muzamil Andrabi, Munir Ahmad Wani, and Nisar A. Chowdri. "A Giant Tumour of Breast: Phyllodes Tumour." JMS SKIMS 21, no. 2 (January 4, 2019): 125. http://dx.doi.org/10.33883/jms.v21i2.362.

Full text
Abstract:
Phyllodes tumour of breast is a rare fibro-epithelial tumour of the breast accounting for less than 1% of the tumours of breast. They are mostly found in females between 45-49 years of age; in contrast, invasive carcinomas of the breast are commonly seen a decade later. They are fast growing tumours with a median size of 4 cm and can grow upto 40 cm. They may be considered benign (58%), borderline (12%), or malignant (30%) depending on histological features of stromal cellularity, tumour infiltration at edge, and mitotic activity. JMS 2018: 21 (2):125
APA, Harvard, Vancouver, ISO, and other styles
42

Huang, G., S. Dong, L. Wan, and P. Liu. "Kinetic analysis of experimental rabbit tumour and inflammation model with 18F-FDG PET/CT." Nuklearmedizin 48, no. 04 (2009): 153–58. http://dx.doi.org/10.3413/nukmed-0201.

Full text
Abstract:
SummaryNon-specific accumulation of 18F-FDG by both tumour and inflammatory lesions can make diagnostic analysis difficult. Our aim was to explore the difference in 18F-FDG uptake kinetics between tumour and inflammatory cells. To this end, we investigated VX2 tumour lesions and inflammatory lesions in rabbits. Methods: Six rabbits with VX2 tumour cells transplanted into one forelimb muscle and inflammatory lesions induced by turpentine oil in the contralateral forelimb were scanned for 60 minutes post 18F-FDG injection. Imaging data was analyzed with the standard 2-tissue-compartment model. Parameters, VB, Ki, K1, k2, k3, k4, were compared between tumour and inflammatory lesions. SUV and dual time scan methods were also compared in the experiment. Results: Time activity curves of VX2 tumour lesions showed a characteristic pattern of gradually increasing 18F-FDG uptake up to 60 min, whereas, 18F-FDG uptake in inflammatory lesions increased more slowly than in tumours. Parameters estimated from the uptake process showed that forward transport constant, K1, and influx constant, Ki, values in VX2 tumour lesions (0.186 ± 0.053 and 0.048 ± 0.014, respectively) was significantly higher than that in inflammatory lesions (0.129 ± 0.024 and 0.022 ± 0.007, respectively) (p < 0.05). In contrast, mean values of VB, k2, k3 and k4 derived from VX2 tumours were not significantly different from that of inflammatory lesions. SUVs at 60 minutes post 18F-FDG injection were also significantly higher in the VX2 tumor lesions than in the inflammatory lesions. Retention index (RI) was not significantly different between VX2 tumours and inflammatory lesions (1.134 ± 0.076 vs. 1.060 ± 0.058, p > 0.05). Conclusion: Different kinetic parameters (Ki, K1, k3) exist between inflammatory and tumour lesions.
APA, Harvard, Vancouver, ISO, and other styles
43

Agarwala, S., and AK Singal. "Tumour markers in pediatric solid tumours." Journal of Indian Association of Pediatric Surgeons 10, no. 3 (2005): 183. http://dx.doi.org/10.4103/0971-9261.16974.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Rennie, Winston J., and Robert U. Ashford. "Imaging quiz: tumours and tumour mimics." Orthopaedics and Trauma 26, no. 1 (February 2012): 33–37. http://dx.doi.org/10.1016/j.mporth.2011.07.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Ellis, I. O. "Tumour markers and origin of tumours." Biomedicine & Pharmacotherapy 47, no. 5 (January 1993): 219. http://dx.doi.org/10.1016/0753-3322(93)90060-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Aluja Jaramillo, F., F. Gutierrez, and S. Bhalla. "Pleural tumours and tumour-like lesions." Clinical Radiology 73, no. 12 (December 2018): 1014–24. http://dx.doi.org/10.1016/j.crad.2018.07.093.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Grötzinger, Carsten. "Tumour Biology of Gastroenteropancreatic Neuroendocrine Tumours." Neuroendocrinology 80, no. 1 (2004): 8–11. http://dx.doi.org/10.1159/000080732.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Rustin, G. J. "Tumour markers in germ cell tumours." BMJ 292, no. 6522 (March 15, 1986): 713–14. http://dx.doi.org/10.1136/bmj.292.6522.713.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Metcalfe, S., and W. G. Jones. "Tumour markers in germ cell tumours." BMJ 292, no. 6530 (May 10, 1986): 1275. http://dx.doi.org/10.1136/bmj.292.6530.1275-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Ionescu, Sebastian, Mihai Mocanu, Andrei Bogdan, Diana Stanescu, Beatrice Bunea, and Alexandra Dobrescu. "Renal tumours in children - Wilms tumour." Bulletin of the Academy of Sciences of Moldova. Medical Sciences, no. 2(73) (November 2022): 32–37. http://dx.doi.org/10.52692/1857-0011.2022.2-73.04.

Full text
Abstract:
Renal tumours represent between 4.4 and 6.3% of all malignant tumours of the children, which requires a thorough knowledge of the types of tumours that can appear at this age group with the purpose of diagnosing and adequately treating these pathologies.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Tumour' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography